WHO recommended Ebola survivors' blood to treat EVD

Sep 6, 2014 05:15 IST

The World Health Organization (WHO) on 5 September 2014 announced to use the Ebola survivors' blood to treat Ebola Virus Disease (EVD). The announcement was done in Geneva. It is an experimental Ebola treatment as there is no licensed treatment.
Experts opined that the antibodies in the blood of people who have survived Ebola might help other patients stave off the virus long enough for their own immune systems to respond. It was noted that survivor's blood was first used to treat Ebola patients in a 1995 outbreak in rural conditions of Africa.
But, the blood from survivors would have to be screened for HIV, malaria and other diseases before being used as a treatment.


About Blood medicine
• Studies on the 1995 outbreak of Ebola in Democratic Republic of Congo showed seven out of eight people survived after being given the blood therapy.
• People, who survived from Ebola produces antibodies in their blood to combat Ebola infection. In theory, those antibodies can be transferred to a sick patient to give a boost to their immune system.

About Ebola virus disease (EVD)
• High fever, Internal or external bleeding and central nervous system damage are the main symptoms of Ebola.
• Infected to other through blood and saliva
• Virus takes two to 21 days to incubate.
• There is no proven vaccine or cure
• Fruit bats are considered to be virus's natural host.

 

Is this article important for exams ? Yes34 People Agreed
Read more Current Affairs on: WHO , Ebola , Blood

DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK